Adjusted EBITDA for VITAS, excluding Medicare Cap, was $66.8 million, flat with prior year, with margin at 16.2%, down 163 basis points due to admitting more short-stay patients.
Admissions at VITAS totaled 17,545, a 1.2% increase from Q2 2024, or 4.9% excluding transfers from the 2024 Covenant Health acquisition.
Average daily census at VITAS increased 6.1% to 22,318. Hospital-directed admissions increased 9.1%, while home-based, nursing home, and assisted living admissions declined.
Average length of stay increased to 137.1 days from 100.6 days in Q2 2024, reflecting effects of community access initiative patients.
Average revenue per patient per day was $207.3, 350 basis points above prior year.
Roto-Rooter adjusted EBITDA was $48.6 million, down 18.7% from prior year, with margin at 21.8%, a 517 basis point decline due to labor inefficiencies, higher commissions, casualty and workers' comp costs, and increased paid search marketing costs.
Roto-Rooter revenue increased 0.6% in Q2 2025, with branch residential revenue up 0.9% and commercial revenue up 4.4%. Independent contractor revenue declined 4.4%.
VITAS net revenue was $396.2 million in Q2 2025, up 5.8% from prior year, driven by a 6.1% increase in days of care and a 4.2% Medicare reimbursement rate increase.
Dafinchi